Investigators sought to compare the prognostic value of sentinel lymph node status vs Breslow thickness in patients with cutaneous melanoma.
The likelihood for development of cutaneous melanoma may be greater for individuals with iris pigmented lesions, according to a study.
Investigators sought to evaluate whether age is associated with risk for immune-related adverse events among patients with metastatic melanoma treated with immunotherapy.
Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.
iPSC vaccine prevented tumor growth in syngeneic murine breast CA, mesothelioma, melanoma models
A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.
The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination TherapyOctober 20, 2017
[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care ProvidersAugust 11, 2017
Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.
Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.
Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Sign Up for Free e-newsletters
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- National Cancer Drug Shortages Unknown to Many Patients
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|